Sarcomatrix Advances Lead Compound S-969 to Large Animal Studies for Muscular Dystrophy
RENO, NV, UNITED STATES, May 13, 2024 /EINPresswire.com/ — Sarcomatrix, a pioneering company in the development of innovative treatments for […]
Press Release
Press Release
Press Release
Understanding Sarcopenia: The Crucial Role of Declining α7β1 Integrin Expression in Aging Muscles.
Sarcopenia, the progressive loss of muscle mass and strength that occurs with aging, is a significant health concern, especially in
Press Release
How upregulating α7β1 integrin might compensate for the lack of dystrophin and DGC in individuals living with Duchenne or Beckers Muscular Dystrophy.
Duchenne and Becker muscular dystrophies (DMD and BMD, respectively) are caused by mutations in the dystrophin gene, leading to the
Press Release
Sarcomatrix Therapeutics Corp.’s exclusive research Partner Strykagen Awarded SBIR Phase 2 Grant from the National Institutes of Health (NIH) to advance small molecules promoting muscle regeneration.
RENO, N.V., Sept. 15, 2023 /Businesswire/ — Strykagen Corp. the exclusive research partner of Sarcomatrix Therapeutics, Corp., a clinical-stage biotechnology company focused on
Press Release
Laminin-111 is a potential first-in-class protein replacement therapy directed to LAMA2-Related Dystrophies – patients, currently in investigational preclinical studies
RENO, NEVADA Mar. 10, 2023 /PRNewswire/ – Sarcomatrix acquired rhLaminin-111 as a potential treatment for LAMA2-Related Dystrophies, a rare, life-threatening
